A Phase II Study of Anlotinib in MTC Patients (ALTN/MTC)
Phase 2 Study of Anlotinib in Advanced Medullary Thyroid Carcinoma
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Listed as NCT01874873, this PHASE2 trial focuses on Tumor and remains completed. Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., it has been updated 8 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jan 2019 — Jun 2019 [monthly]
Unknown Status PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Unknown Status PHASE2
-
May 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — May 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .